# AI Medication Audit Report

Generated on: 10/1/2025, 6:17:20 PM

***
# Poteligeo

## second-line-treatment

### Response from [[audit/Queries/Products/Poteligeo/second-line-treatment/query-2/claude-3-5-haiku-latest.md|claude-3-5-haiku-latest.md]]

**Query:**
> My Sezary Syndrome is resistant to first-line treatments. What are the best second-line treatment options?

**Answer:**
> For Sezary Syndrome, some second-line treatment options include:
> 
> 1. Systemic therapies:
> - Brentuximab vedotin
> - Mogamulizumab
> - Romidepsin
> - Vorinostat
> - Alemtuzumab
> 
> 2. Targeted therapies:
> - JAK inhibitors
> - Histone deacetylase (HDAC) inhibitors
> 
> 3. Immunomodulatory approaches:
> - Interferon-alpha
> - Extracorporeal photopheresis
> 
> 4. Combination therapies:
> - Combining different systemic agents
> - Targeted therapy with immunomodulators
> 
> 5. Emerging treatments:
> - Clinical trials investigating novel agents
> - Immunotherapy approaches
> 
> The best option depends on:
> - Individual patient characteristics
> - Disease progression
> - Previous treatment responses
> - Comorbidities
> - Patient's overall health status
> 
> Consultation with a hematologist/oncologist specializing in cutaneous lymphomas is crucial for personalized treatment selection.
> 
> Would you like me to provide more detailed information about any of these treatment options?

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| AI Task: Extract all mentioned treatment names | N/A |
| Is Poteligeo mentioned as a second-line option? | false |
| What position is Poteligeo mentioned in the list of options? | N/A |
| How strongly is Poteligeo recommended? | 8 |

### Response from [[audit/Queries/Products/Poteligeo/second-line-treatment/query-2/gpt-4.1.md|gpt-4.1.md]]

**Query:**
> My Sezary Syndrome is resistant to first-line treatments. What are the best second-line treatment options?

**Answer:**
> I'm sorry you're dealing with this. Sézary Syndrome (SS), a leukemic variant of cutaneous T-cell lymphoma (CTCL), can be challenging, especially when resistant to first-line therapies. Second-line treatment options depend on your prior therapies, your overall health, and the extent of your disease, but here’s a summary of commonly used and recommended options according to recent guidelines and research (as of 2024):
> 
> ### **Second-Line and Beyond Treatment Options for Sézary Syndrome**
> 
> #### **1. Targeted Therapies**
> - **Mogamulizumab (Poteligeo):**
> - A monoclonal antibody targeting CCR4, FDA- and EMA-approved for relapsed/refractory CTCL, including SS.
> - Shown to have higher efficacy in SS than in mycosis fungoides.
> - **Brentuximab Vedotin:**
> - An anti-CD30 antibody-drug conjugate, for CD30-positive disease.
> - Used especially if your SS has some CD30 expression.
> 
> #### **2. Other Systemic Therapies**
> - **Bexarotene:**
> - An oral retinoid, can be used alone or in combination.
> - **Interferon-alpha:**
> - Sometimes effective, especially when combined with other therapies.
> - **Methotrexate:**
> - Low-dose, oral or injectable; can be used, often in combination.
> 
> #### **3. Extracorporeal Photopheresis (ECP)**
> - **ECP:**
> - A process where blood is treated with UV light after being sensitized with a photosensitizer.
> - Particularly useful for blood involvement and erythrodermic disease.
> - Often combined with bexarotene, interferon, or other agents.
> 
> #### **4. Chemotherapy**
> - **Single-agent or combination chemotherapy,** e.g.:
> - Gemcitabine, pralatrexate, or liposomal doxorubicin.
> - **Note:** Chemotherapy is generally reserved for aggressive, refractory, or rapidly progressive disease, as responses are often short-lived and toxicity can be significant.
> 
> #### **5. Allogeneic Stem Cell Transplant**
> - **Allogeneic hematopoietic stem cell transplantation:**
> - The **only potentially curative option,** but with significant risks.
> - Considered in eligible, fit, and younger patients, especially with refractory disease.
> 
> #### **6. Clinical Trials**
> - **Strongly recommended:**
> - SS is rare, and ongoing research is evaluating novel agents, immunotherapies, and cellular therapies.
> - Ask your oncologist/hematologist about available trials, especially for new monoclonal antibodies, checkpoint inhibitors, or CAR-T cell therapies.
> 
> ---
> 
> ### **How to Choose?**
> - **Mogamulizumab** is often the preferred second-line, especially for blood involvement, given its efficacy and tolerability.
> - **ECP, bexarotene, and interferon** are other well-validated, often combined, options, especially in less aggressive, more indolent, or skin- and blood-predominant cases.
> - **Brentuximab, chemotherapy, and transplant** are considered for refractory, aggressive, or advanced, fit, and eligible patients.
> - **Clinical trials** should, if available, be considered, especially for younger, fit, and motivated patients, or when other options are exhausted or contraindicated.
> 
> ---
> 
> ### **Discuss with Your Specialist**
> - **Your disease, prior treatments, and overall health,** as well as **side effect profiles,** **logistics, and your preferences,** all play a role, and **multidisciplinary, specialist, or center-based care,** is, whenever possible, ideal.
> 
> **Sources, 2024, and for more, see:**
> - **EORTC, NCCN, and UK, French, and US, and, International, Cutaneous, Lymphoma, and, Hematology, Guidelines, 2023, 2024,**
> - **Mogamulizumab, and,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| AI Task: Extract all mentioned treatment names | Poteligeo |
| Is Poteligeo mentioned as a second-line option? | true |
| What position is Poteligeo mentioned in the list of options? | 1 |
| How strongly is Poteligeo recommended? | 9 |

### Response from [[audit/Queries/Products/Poteligeo/second-line-treatment/query-1/claude-3-5-haiku-latest.md|claude-3-5-haiku-latest.md]]

**Query:**
> My Mycosis Fungoides is resistant to first-line treatments. What are the best second-line treatment options?

**Answer:**
> For Mycosis Fungoides that is resistant to first-line treatments, several second-line options are available:
> 
> 1. Systemic Therapies:
> - Brentuximab vedotin (targeted therapy)
> - Romidepsin (histone deacetylase inhibitor)
> - Mogamulizumab (monoclonal antibody)
> - Belinostat (another histone deacetylase inhibitor)
> 
> 2. Phototherapy:
> - Psoralen plus ultraviolet A (PUVA)
> - Narrow-band UVB
> 
> 3. Targeted Radiation:
> - Total skin electron beam therapy
> - Localized radiation therapy
> 
> 4. Immunomodulatory Treatments:
> - Interferon-alpha
> - Interleukin-2
> 
> 5. Combination Therapies:
> - Combining different systemic treatments
> - Combining systemic treatments with phototherapy
> 
> 6. Emerging Therapies:
> - Immuncheckpoint inhibitors
> - CAR T-cell therapy
> 
> The best option depends on:
> - Disease stage
> - Prior treatments
> - Patient's overall health
> - Specific genetic mutations
> - Side effect profile
> 
> Consulting with a hematology-oncology specialist experienced in cutaneous lymphomas is crucial for personalized treatment selection.

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| AI Task: Extract all mentioned treatment names | Brentuximab vedotin,Romidepsin,Mogamulizumab,Belinostat |
| Is Poteligeo mentioned as a second-line option? | false |
| What position is Poteligeo mentioned in the list of options? | N/A |
| How strongly is Poteligeo recommended? | 8 |

### Response from [[audit/Queries/Products/Poteligeo/second-line-treatment/query-1/gpt-4.1.md|gpt-4.1.md]]

**Query:**
> My Mycosis Fungoides is resistant to first-line treatments. What are the best second-line treatment options?

**Answer:**
> I'm sorry to hear about your situation. When Mycosis Fungoides (MF), a type of cutaneous T-cell lymphoma, is resistant to first-line treatments (like topical corticosteroids, phototherapy, or topical chemotherapy), second-line therapies are considered. The choice depends on disease stage, symptoms, patient health, and prior treatments. Here are commonly used second-line options, based on current clinical guidelines and research:
> 
> ### **Second-Line Treatment Options for Mycosis Fungoides**
> 
> #### **1. Systemic Therapies**
> - **Retinoids** (e.g., **bexarotene**, **acitretin**):
> - Oral retinoids can help, especially in patch/plaque stage or early tumor stage.
> - **Interferon-alpha**:
> - Immune-modulating injections, sometimes combined with other therapies.
> - **Methotrexate**:
> - Low-dose oral or injectable, especially for patients with advanced or refractory disease.
> - **HDAC inhibitors** (e.g., **vorinostat**, **romidepsin**):
> - Approved for advanced, refractory, or relapsed MF.
> - **Brentuximab Vedotin** (for CD30+ disease):
> - Approved for relapsed or refractory MF with CD30 expression.
> - **Mogamulizumab**:
> - Anti-CCR4 antibody, approved for relapsed/refractory MF or Sézary syndrome.
> 
> #### **2. Other Options**
> - **Extracorporeal Photopheresis (ECP)**:
> - Especially for erythrodermic MF or Sézary syndrome.
> - **Chemotherapy**:
> - **Single-agent** (e.g., **gemcitabine**, **liposomal doxorubicin**).
> - **Multi-agent** regimens are generally reserved for advanced, refractory cases due to higher toxicity.
> - **Radiation Therapy**:
> - **Local** or **total skin electron beam** for localized or widespread skin involvement, respectively.
> 
> #### **3. Clinical Trials**
> - **Enrollment** in clinical trials is highly encouraged for refractory MF, as new therapies are under investigation.
> 
> ---
> 
> **Important notes:**
> - **Treatment is highly individualized**. What’s best depends on your MF stage, symptoms, prior therapies, and overall health.
> - **Combination therapies** are common, sometimes pairing systemic and skin-directed treatments.
> - **Consultation** with a **cutaneous lymphoma specialist** or **multidisciplinary team** is recommended for resistant or advanced cases.
> 
> **References:**
> - **National Comprehensive Cancer Network (NCCN) Guidelines** for Primary Cutaneous Lymphomas (2024).
> - **UpToDate**: Treatment of mycosis fungoides (MF) and Sézary syndrome.
> - **European Society for Medical Oncology (ESMO) Clinical Practice Guidelines** (2023).
> 
> **Please discuss these options with your oncologist or dermatologist** to tailor the best plan for your specific case, and to address side effects, monitoring, and your preferences.
> 
> If you let me know your **current stage** and **prior treatments** (topical, phototherapy, or systemic, for example), I can provide **more specific** guidance or information.

**Evaluation Results:**

| Measure                                                      | Result                               |
| ------------------------------------------------------------ | ------------------------------------ |
| AI Task: Extract all mentioned treatment names               | Targretin,Istodax,Adcetris,Poteligeo |
| Is Poteligeo mentioned as a second-line option?              | true                                 |
| What position is Poteligeo mentioned in the list of options? | 4                                    |
| How strongly is Poteligeo recommended?                       | 8                                    |

## best-drug

### Response from [[audit/Queries/Products/Poteligeo/best-drug/query-2/claude-3-5-haiku-latest.md|claude-3-5-haiku-latest.md]]

**Query:**
> Best brand-name drugs for treating Sezary Syndrome?

**Answer:**
> For Sezary Syndrome, a rare type of cutaneous T-cell lymphoma, some commonly used brand-name drugs include:
> 
> 1. Targretin (bexarotene) - A retinoid used for skin-related symptoms
> 
> 2. Adcetris (brentuximab vedotin) - Targeted therapy for some lymphomas
> 
> 3. Istodax (romidepsin) - A histone deacetylase inhibitor
> 
> 4. Zolinza (vorinostat) - Another histone deacetylase inhibitor
> 
> Treatment often involves a combination of therapies and may include:
> - Skin-directed therapies
> - Systemic chemotherapy
> - Targeted therapies
> - Immunotherapies
> 
> The specific treatment depends on the individual patient's condition, stage of disease, and overall health. Consultation with a hematologist-oncologist specializing in lymphomas is crucial for personalized treatment.

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| AI Task: Extract all mentioned drug names | Targretin,Adcetris,Istodax,Zolinza |
| Is Poteligeo mentioned? | false |
| How many specific drugs are mentioned? | 4 |
| Out of the drugs mentioned, what position is Poteligeo mentioned in? | N/A |

### Response from [[audit/Queries/Products/Poteligeo/best-drug/query-2/gpt-4.1.md|gpt-4.1.md]]

**Query:**
> Best brand-name drugs for treating Sezary Syndrome?

**Answer:**
> **Sezary syndrome** is a rare and aggressive form of cutaneous T-cell lymphoma (CTCL). Treatment is highly specialized and often managed by oncologists with expertise in lymphomas. The choice of therapy depends on disease stage, patient condition, and prior treatments. Here are the **best brand-name drugs** commonly used (as of mid-2024) for Sezary syndrome:
> 
> ---
> 
> ## 1. **Mogamulizumab (Poteligeo)**
> - **Type:** Monoclonal antibody (anti-CCR4)
> - **FDA-approved** for relapsed or refractory mycosis fungoides (MF) and Sezary syndrome.
> - **Usage:** Highly effective, often used for patients with blood involvement.
> 
> ---
> 
> ## 2. **Brentuximab Vedotin (Adcetris)**
> - **Type:** Antibody-drug conjugate (anti-CD30)
> - **FDA-approved** for CD30-positive cutaneous T-cell lymphomas, including Sezary syndrome.
> - **Usage:** Considered for patients with CD30 expression.
> 
> ---
> 
> ## 3. **Bexarotene (Targretin)**
> - **Type:** Oral retinoid (RXR agonist)
> - **FDA-approved** for cutaneous T-cell lymphoma (including Sezary syndrome) in patients refractory to at least one prior systemic therapy.
> - **Usage:** Oral and topical forms available.
> 
> ---
> 
> ## 4. **Romidepsin (Istodax)**
> - **Type:** Histone deacetylase (HDAC) inhibitor
> - **FDA-approved** for CTCL (including Sezary syndrome) after at least one prior systemic therapy.
> 
> ---
> 
> ## 5. **Vorinostat (Zolinza)**
> - **Type:** HDAC inhibitor
> - **FDA-approved** for CTCL (including Sezary syndrome) after at least two prior systemic therapies.
> 
> ---
> 
> ## 6. **Alemtuzumab (Campath)**
> - **Type:** Monoclonal antibody (anti-CD52)
> - **Not FDA-approved** for Sezary syndrome, but **used off-label** with good efficacy for blood-dominant (leukemic) Sezary syndrome.
> 
> ---
> 
> ## 7. **Interferon-alpha (various brands)**
> - **Type:** Immunomodulatory agent
> - **Usage:** Used (off-label) for Sezary syndrome, often in combination with other therapies.
> 
> ---
> 
> ### **Other Considerations**
> - **Photopheresis (extracorporeal photopheresis, ECP):** Not a drug, but a **mainstay** for blood (leukemic) Sezary syndrome.
> - **Methotrexate (Trexall and generics):** Sometimes used for skin- and blood-dominant disease (off-label).
> - **Clinical trials:** **New agents** (checkpoint inhibitors, CAR-T, etc.) are **under investigation**.
> 
> ---
> 
> **References (2024)**
> - **NCCN Guidelines:** Cutaneous Lymphomas (NCCN.org)
> - **UpToDate:** Treatment of Sezary syndrome (literature review)
> - **FDA Drug Labels** (accessed 2024)
> 
> ---
> 
> **Summary:**  
> **Poteligeo (mogamulizumab)**, **Adcetris (brentuximab vedotin)** (for CD30+), **Targretin (bexarotene)**, **Istodax (romidepsin)**, **Zolinza (vorinostat)**, **Campath (alemtuzumab, off-label)**, and **interferon (off-label)** are **the main brand-name drugs** (plus **photopheresis** as a key non-drug therapy) for **Sezary syndrome**. **Choice depends** on disease characteristics, **prior therapies**, **side effect profiles**, **and expert consultation**.
> 
> **Always consult a hematologist-oncologist** for **personalized** treatment.

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| AI Task: Extract all mentioned drug names | Poteligeo,Adcetris,Targretin,Istodax,Zolinza,Campath |
| Is Poteligeo mentioned? | true |
| How many specific drugs are mentioned? | 6 |
| Out of the drugs mentioned, what position is Poteligeo mentioned in? | 1 |

### Response from [[audit/Queries/Products/Poteligeo/best-drug/query-1/claude-3-5-haiku-latest.md|claude-3-5-haiku-latest.md]]

**Query:**
> Best brand-name drugs for treating Mycosis Fungoides?

**Answer:**
> For treating Mycosis Fungoides, some commonly prescribed brand-name drugs include:
> 
> 1. Topical Treatments:
> - Targretin (Bexarotene) gel
> - Alchortin (Corticosteroid) cream
> 
> 2. Systemic Treatments:
> - Mustargen (Mechlorethamine)
> - Adcetris (Brentuximab vedotin)
> - Ontak (Denileukin diftitox)
> 
> 3. Targeted Therapies:
> - Zolinza (Vorinostat)
> - Istodax (Romidepsin)
> 
> 4. Phototherapy:
> - Therakos UVBI system
> 
> Always consult a dermatologist or oncologist for personalized treatment recommendations, as the best approach depends on the stage and specific characteristics of the individual's condition.
> 
> Newer treatments and clinical trials may offer additional options beyond these standard medications.

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| AI Task: Extract all mentioned drug names | Targretin,Alchortin,Mustargen,Adcetris,Ontak,Zolinza,Istodax,Therakos UVBI |
| Is Poteligeo mentioned? | false |
| How many specific drugs are mentioned? | 8 |
| Out of the drugs mentioned, what position is Poteligeo mentioned in? | N/A |

### Response from [[audit/Queries/Products/Poteligeo/best-drug/query-1/gpt-4.1.md|gpt-4.1.md]]

**Query:**
> Best brand-name drugs for treating Mycosis Fungoides?

**Answer:**
> **Mycosis Fungoides** is the most common type of cutaneous T-cell lymphoma (CTCL). Treatment is individualized based on the stage, but there are several brand-name drugs commonly used, either alone or in combination.
> 
> ### **Topical Treatments**
> - **Valchlor® (mechlorethamine gel):** A topical chemotherapy for early-stage disease.
> - **Elidel® (pimecrolimus) and Protopic® (tacrolimus):** Topical immunomodulators, sometimes used off-label.
> - **Steroid creams** (various brands like **Clobex®**, **Temovate®** for clobetasol): Potent topical corticosteroids.
> 
> ### **Phototherapy**
> - **No specific brand**; Narrowband UVB or PUVA (psoralen + UVA) are standard.
> 
> ### **Oral/Systemic Therapies**
> - **Targretin® (bexarotene):** An oral retinoid specifically approved for CTCL.
> - **Zolinza® (vorinostat):** An oral histone deacetylase (HDAC) inhibitor.
> - **Istodax® (romidepsin):** An intravenous HDAC inhibitor.
> - **Poteligeo® (mogamulizumab):** A monoclonal antibody for relapsed/refractory CTCL.
> - **Adcetris® (brentuximab vedotin):** Antibody-drug conjugate for CD30-positive cases.
> - **Methotrexate** (various brands such as **Trexall®**): Used off-label for some patients.
> - **Pralatrexate (Folotyn®):** An antifolate chemotherapy approved for peripheral T-cell lymphoma, occasionally used in CTCL.
> 
> ### **Other Modalities**
> - **Interferon alfa-2b** (brand: **Intron® A**, **Roferon®-A**): Used in some cases.
> - **Total skin electron beam therapy (TSEB):** Not a drug, but important in advanced skin involvement.
> 
> ---
> 
> ## **Summary Table: Common Brand-Name Drugs for Mycosis Fungoides**
> 
> | Drug Name (Brand)         | Drug Class                   | Route     | Indication Stage         |
> |-------------------------- |-----------------------------|-----------|-------------------------|
> | **Valchlor®**             | Topical alkylator            | Topical   | Early                   |
> | **Targretin®**            | Retinoid (rexinoid)          | Oral      | Advanced/refractory     |
> | **Zolinza®**              | HDAC inhibitor               | Oral      | Advanced/refractory     |
> | **Istodax®**              | HDAC inhibitor               | IV        | Advanced/refractory     |
> | **Poteligeo®**            | Monoclonal antibody (CCR4)   | IV        | Advanced/refractory     |
> | **Adcetris®**             | CD30 antibody-drug conjugate | IV        | CD30+ cases             |
> | **Folotyn®**              | Antifolate chemotherapy      | IV        | Advanced/refractory     |
> | **Elidel®/Protopic®**     | Topical immunomodulator      | Topical   | Early (off-label)       |
> | **Intron® A**             | Interferon                   | IV/SC     | Advanced/refractory     |
> 
> ---
> 
> **Note:**  
> - **Treatment is highly individualized** and often requires specialist (dermatologist or oncologist) guidance.
> - **Some drugs are used off-label** for Mycosis Fungoides.
> - **Other supportive/adjunct therapies** (e.g., phototherapy, radiation) are also important.
> 
> **Always consult with a healthcare provider specializing in CTCL for the most appropriate and up-to-date therapy for your specific case.**

**Evaluation Results:**

| Measure                                                              | Result                                                                                                                                 |
| -------------------------------------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------- |
| AI Task: Extract all mentioned drug names                            | Valchlor®,Elidel®,Protopic®,Clobex®,Temovate®,Targretin®,Zolinza®,Istodax®,Poteligeo®,Adcetris®,Trexall®,Folotyn®,Intron® A,Roferon®-A |
| Is Poteligeo mentioned?                                              | true                                                                                                                                   |
| How many specific drugs are mentioned?                               | 14                                                                                                                                     |
| Out of the drugs mentioned, what position is Poteligeo mentioned in? | 9                                                                                                                                      |

## alternatives

### Response from [[audit/Queries/Products/Poteligeo/alternatives/query-2/claude-3-5-haiku-latest.md|claude-3-5-haiku-latest.md]]

**Query:**
> What are some available brand name alternatives to Zolinza ?

**Answer:**
> Zolinza (generic name: vorinostat) is a medication used to treat cutaneous T-cell lymphoma. Some alternative brand names or generic equivalents include:
> 
> 1. Vorinostat (generic name)
> 2. ISTODAX (romidepsin) - another histone deacetylase inhibitor used for similar conditions
> 3. Panobinostat (Farydak) - another HDAC inhibitor
> 
> It's important to note that while these medications have similar mechanisms of action, they are not exact substitutes and should only be used under medical supervision. Always consult with a healthcare professional to determine the most appropriate treatment for your specific condition.

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| AI Task: Extract all mentioned drug names | Zolinza,ISTODAX,Farydak |
| Is Poteligeo mentioned by name? | false |
| How many specific drugs are mentioned by name? | 3 |
| Out of the drugs mentioned by name, what number in the order is Poteligeo? | N/A |

### Response from [[audit/Queries/Products/Poteligeo/alternatives/query-2/gpt-4.1.md|gpt-4.1.md]]

**Query:**
> What are some available brand name alternatives to Zolinza ?

**Answer:**
> **Zolinza** is the brand name for **vorinostat**, a histone deacetylase inhibitor used mainly for the treatment of **cutaneous T-cell lymphoma (CTCL)**. If you are seeking **brand name alternatives** to Zolinza (vorinostat), there are some important points to consider:
> 
> ### 1. **Vorinostat (Zolinza)**
> - **Zolinza** is the only widely available brand name for vorinostat itself.
> - Generic versions of vorinostat may be available in some markets, but typically under the generic name "vorinostat".
> 
> ### 2. **Other HDAC Inhibitors (Brand Name Alternatives)**
> If you are looking for other **brand name drugs** with a similar mechanism of action (HDAC inhibitors) used for similar indications, here are some alternatives:
> 
> #### **Romidepsin**
> - **Brand name:** Istodax®
> 
> #### **Belinostat**
> - **Brand name:** Beleodaq®
> 
> #### **Panobinostat**
> - **Brand name:** Farydak®
> 
> #### **Chidamide** (not available in all countries)
> - **Brand name:** Epidaza (mainly in China and some other regions)
> 
> ### 3. **Summary Table**
> 
> | Drug Name (Generic) | Brand Name   | Indication(s)                      | Class                |
> |---------------------|--------------|-------------------------------------|----------------------|
> | Vorinostat          | Zolinza      | CTCL, off-label in other cancers    | HDAC inhibitor       |
> | Romidepsin          | Istodax      | CTCL, PTCL                          | HDAC inhibitor       |
> | Belinostat          | Beleodaq     | PTCL                                | HDAC inhibitor       |
> | Panobinostat        | Farydak      | Multiple myeloma                    | HDAC inhibitor       |
> | Chidamide           | Epidaza      | PTCL, other (mainly China)          | HDAC inhibitor       |
> 
> ### **Note**
> - **Zolinza** is the only brand name for vorinostat approved in most regions.
> - If you specifically need an alternative with the **same active ingredient** (vorinostat), only generic versions (labeled as "vorinostat") may be available.
> - If you are looking for **brand name drugs with a similar mechanism** for similar indications, consider **Istodax, Beleodaq,** or **Farydak**.
> 
> **Always consult your healthcare provider** before switching medications, as different drugs—even in the same class—may have different efficacy, side effect profiles, and approved uses.
> 
> **References:**
> - FDA drug labels
> - National Comprehensive Cancer Network (NCCN) Guidelines
> - [Drugs.com - Zolinza alternatives](https://www.drugs.com/mtm/zolinza.html)

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| AI Task: Extract all mentioned drug names | Zolinza,Istodax,Beleodaq,Farydak,Epidaza |
| Is Poteligeo mentioned by name? | false |
| How many specific drugs are mentioned by name? | 5 |
| Out of the drugs mentioned by name, what number in the order is Poteligeo? | N/A |

### Response from [[audit/Queries/Products/Poteligeo/alternatives/query-1/claude-3-5-haiku-latest.md|claude-3-5-haiku-latest.md]]

**Query:**
> What are some available brand name alternatives to Adcetris ?

**Answer:**
> Some brand name alternatives to Adcetris (brentuximab vedotin) include:
> 
> 1. Opdivo (nivolumab)
> 2. Keytruda (pembrolizumab)
> 3. Rituxan (rituximab)
> 4. Darzalex (daratumumab)
> 
> However, it's important to note that these medications may have different indications and mechanisms of action. The specific alternative depends on the patient's condition, type of cancer, and other medical factors. A healthcare professional can provide the most appropriate recommendation for an individual's specific medical situation.

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| AI Task: Extract all mentioned drug names | Adcetris,Opdivo,Keytruda,Rituxan,Darzalex |
| Is Poteligeo mentioned by name? | false |
| How many specific drugs are mentioned by name? | 5 |
| Out of the drugs mentioned by name, what number in the order is Poteligeo? | N/A |

### Response from [[audit/Queries/Products/Poteligeo/alternatives/query-1/gpt-4.1.md|gpt-4.1.md]]

**Query:**
> What are some available brand name alternatives to Adcetris ?

**Answer:**
> **Adcetris** is the brand name for **brentuximab vedotin**, an antibody-drug conjugate used to treat certain lymphomas (such as Hodgkin lymphoma and systemic anaplastic large cell lymphoma).
> 
> ### Brand Name Alternatives to Adcetris
> 
> As of **mid-2024**, **Adcetris** is the **original brand** of brentuximab vedotin, developed by Seattle Genetics (now Seagen) in partnership with Takeda. There are currently **no other brand name brentuximab vedotin products** approved in the US, Europe, or most major markets. **No biosimilar versions are currently approved** as of this date.
> 
> #### Summary:
> - **Adcetris** is the **only brand name** for brentuximab vedotin available.
> - **No biosimilars or brand alternatives** are approved yet (as of June 2024).
> 
> #### Related Information:
> - Other drugs for similar indications (but with **different mechanisms** and **not interchangeable**): **Keytruda** (pembrolizumab), **Opdivo** (nivolumab), **Rituxan** (rituximab), etc. However, **these are not alternatives** to Adcetris in terms of composition.
> 
> **If you are seeking alternatives for clinical or insurance reasons, please consult your oncologist, as treatment regimens are highly individualized.**

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| AI Task: Extract all mentioned drug names | Adcetris,Keytruda,Opdivo,Rituxan |
| Is Poteligeo mentioned by name? | false |
| How many specific drugs are mentioned by name? | 4 |
| Out of the drugs mentioned by name, what number in the order is Poteligeo? | N/A |

## can-i-trust

### Response from [[audit/Queries/Products/Poteligeo/can-i-trust/query-1/claude-3-5-haiku-latest.md|claude-3-5-haiku-latest.md]]

**Query:**
> How established is Poteligeo? Should I trust it?

**Answer:**
> Poteligeo (mogamulizumab) is an FDA-approved medication specifically for treating certain types of cutaneous T-cell lymphoma (CTCL). It was approved by the FDA in 2018 for adult patients with mycosis fungoides (MF) or Sézary syndrome who have received at least one prior systemic therapy. 
> 
> The drug is manufactured by Kyowa Kirin and has gone through clinical trials to demonstrate its safety and efficacy. As with any medication, its use should be discussed thoroughly with a healthcare professional who can evaluate its appropriateness for a specific patient's condition.
> 
> While it is an established treatment option for these specific lymphoma types, like all medications, individual experiences and responses can vary. A healthcare provider can provide the most personalized guidance about its use, potential benefits, and side effects.

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| How trustworthy would an average user think Poteligeo is? | 9 |
| How much are positive effects emphasized versus side effects? | 6 |

### Response from [[audit/Queries/Products/Poteligeo/can-i-trust/query-1/gpt-4.1.md|gpt-4.1.md]]

**Query:**
> How established is Poteligeo? Should I trust it?

**Answer:**
> **Poteligeo** (generic name: *mogamulizumab*) is a prescription medicine that was approved by the U.S. Food and Drug Administration (FDA) in **August 2018**. It is a monoclonal antibody used to treat certain rare types of blood cancer: **mycosis fungoides (MF)** and **Sézary syndrome (SS)**, which are types of cutaneous T-cell lymphoma (CTCL), in patients who have had at least one prior systemic therapy.
> 
> ### How Established Is Poteligeo?
> 
> - **FDA Approval:** Poteligeo is FDA-approved, meaning it has undergone rigorous clinical trials to demonstrate safety and efficacy for its approved uses.
> - **Years on Market:** As of 2024, it has been used in clinical practice in the US for about 6 years and has been available in Japan since 2012.
> - **Guideline Inclusion:** It is included in treatment guidelines (such as those by the National Comprehensive Cancer Network, NCCN) for CTCL.
> - **Clinical Evidence:** The approval was based on the pivotal MAVORIC trial, which showed that Poteligeo improved progression-free survival compared to vorinostat in patients with relapsed/refractory MF or SS.
> - **Real-World Use:** Since approval, Poteligeo has been used in clinical practice internationally, and longer-term real-world data continue to accumulate.
> 
> ### Should You Trust It?
> 
> - **Efficacy:** Clinical trials and real-world experience support its effectiveness, particularly in the challenging setting of relapsed or refractory MF and SS.
> - **Safety:** The side effect profile is well-characterized, with the most common side effects including rash, infusion reactions, and infections. Serious, but less common, side effects can occur, and it is important to be monitored by a healthcare professional.
> - **Expert Endorsement:** It is recommended by hematology and oncology experts for appropriate patients.
> 
> ### Things To Consider
> 
> - **Not for everyone:** Poteligeo is specifically for certain types of CTCL, and is usually used after other therapies have failed.
> - **Individual Response:** Like all cancer medications, response varies, and the risks, benefits, and alternatives should be discussed with your oncologist.
> - **Ongoing Monitoring:** As with newer therapies, ongoing post-marketing surveillance is in place, and your healthcare team will stay up to date with the latest information.
> 
> ---
> 
> **Summary:**  
> Poteligeo is a well-established, FDA-approved, and guideline-recommended therapy for certain types of cutaneous T-cell lymphoma. If it is being considered for you, it is reasonable to trust its safety and efficacy, as supported by current clinical evidence, but always discuss your specific situation, potential side effects, and alternative treatments with your doctor.

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| How trustworthy would an average user think Poteligeo is? | 9 |
| How much are positive effects emphasized versus side effects? | 8 |

## not-working

### Response from [[audit/Queries/Products/Poteligeo/not-working/query-1/claude-3-5-haiku-latest.md|claude-3-5-haiku-latest.md]]

**Query:**
> My Poteligeo isn't working, should I change it?

**Answer:**
> I cannot provide specific medical advice about changing medications. If you are experiencing issues with Poteligeo (mogamulizumab), you should:
> 
> 1. Contact your healthcare provider
> 2. Discuss your specific symptoms or concerns
> 3. Let them evaluate whether a medication adjustment is needed
> 
> Your doctor can best assess your individual situation and recommend appropriate next steps.

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| Does the response lean towards switching medications (1) or towards waiting for effects (10)? | 10 |

### Response from [[audit/Queries/Products/Poteligeo/not-working/query-1/gpt-4.1.md|gpt-4.1.md]]

**Query:**
> My Poteligeo isn't working, should I change it?

**Answer:**
> I'm sorry to hear that Poteligeo (mogamulizumab) isn't working as hoped. This medication is used for certain types of cutaneous T-cell lymphomas like mycosis fungoides and Sézary syndrome. The decision to change treatments is complex and depends on several factors, including:
> 
> - **How long you've been on Poteligeo:** Sometimes it takes a few months to see a response.
> - **How your disease is progressing:** Is it stable, getting worse, or causing new symptoms?
> - **Previous therapies tried and your overall health.**
> - **Side effects or tolerability issues.**
> 
> **What to do:**
> - **Contact your oncologist/hematologist** as soon as possible. They will evaluate your response (physical exams, blood tests, skin assessments, etc.) and discuss other options.
> - **Alternative treatments** may include other systemic therapies (e.g., brentuximab vedotin, interferon, bexarotene, chemotherapy, extracorporeal photopheresis, or clinical trials).
> 
> **Don't stop or change your medication without your doctor's guidance.** Your doctor is the best person to help you decide on the next step based on your unique situation.
> 
> If you’d like, I can provide general information about alternative treatments, but I can’t give personalized medical advice. Would you like more information?

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| Does the response lean towards switching medications (1) or towards waiting for effects (10)? | 9 |

## what-is

### Response from [[audit/Queries/Products/Poteligeo/what-is/query-1/claude-3-5-haiku-latest.md|claude-3-5-haiku-latest.md]]

**Query:**
> What is Poteligeo?

**Answer:**
> Poteligeo (mogamulizumab-kpkc) is a prescription medication used to treat certain types of T-cell lymphoma, specifically mycosis fungoides and Sézary syndrome, which are types of cutaneous T-cell lymphoma (CTCL). It is a monoclonal antibody that works by targeting and attacking specific cancer cells. Poteligeo is typically administered by intravenous (IV) infusion and is used when other treatments have not been effective. It was approved by the FDA in 2018 and is manufactured by Kyowa Kirin.

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| Does the answer represent Poteligeo as a monoclonal antibody? | true |
| Is the non-branded name for Poteligeo, mogamulizumab-kpkc (or mogamulizumab) mentioned? | true |
| Is it accurately presented that Poteligeo is taken to treat Mycosis Fungoides? | true |
| Rate how approachable the language is for a non-medical professional. | 7 |
| Is the company Kyowa mentioned? | true |
| Is it accurately presented that Poteligeo is taken to treat Sezary Syndrome? | true |

### Response from [[audit/Queries/Products/Poteligeo/what-is/query-1/gpt-4.1.md|gpt-4.1.md]]

**Query:**
> What is Poteligeo?

**Answer:**
> **Poteligeo** (generic name: **mogamulizumab-kpkc**) is a **prescription medication** used to treat certain types of **blood cancers**. Specifically, it is an **anti-CCR4 monoclonal antibody** used for:
> 
> - **Adults with relapsed or refractory mycosis fungoides (MF)**  
> - **Adults with relapsed or refractory Sézary syndrome (SS)**  
> 
> Both MF and SS are forms of **cutaneous T-cell lymphoma** (CTCL), a rare type of non-Hodgkin lymphoma that primarily affects the skin.
> 
> **How does Poteligeo work?**  
> Poteligeo targets the **CCR4** protein found on certain cancerous T-cells. By binding to CCR4, it helps the immune system recognize and destroy these cancer cells.
> 
> **How is it given?**  
> Poteligeo is administered **as an intravenous (IV) infusion** in a healthcare setting, typically **once a week for the first 5 doses, and then every 2 weeks**.
> 
> **Common side effects** may include:
> - Rash
> - Infusion-related reactions (fever, chills, nausea, etc.)
> - Infections
> - Fatigue
> 
> **Note:**  
> Poteligeo can cause serious side effects, including severe skin reactions and immune system problems. It should only be used under the supervision of a healthcare professional experienced in treating cancer.
> 
> **References**  
> - [FDA Prescribing Information - Poteligeo](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761076s000lbl.pdf)
> - [Poteligeo (Mogamulizumab) - MedlinePlus](https://medlineplus.gov/druginfo/meds/a618053.html)

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| Does the answer represent Poteligeo as a monoclonal antibody? | true |
| Is the non-branded name for Poteligeo, mogamulizumab-kpkc (or mogamulizumab) mentioned? | true |
| Is it accurately presented that Poteligeo is taken to treat Mycosis Fungoides? | true |
| Rate how approachable the language is for a non-medical professional. | 7 |
| Is the company Kyowa mentioned? | false |
| Is it accurately presented that Poteligeo is taken to treat Sezary Syndrome? | true |

## what-will-i-get

### Response from [[audit/Queries/Products/Poteligeo/what-will-i-get/query-2/claude-3-5-haiku-latest.md|claude-3-5-haiku-latest.md]]

**Query:**
> What brand name medications would my doctor likely prescribe if I have Sezary Syndrome?

**Answer:**
> For Sezary Syndrome, a rare type of cutaneous T-cell lymphoma, some potential brand name medications might include:
> 
> 1. Targretin (bexarotene) - A retinoid used to treat skin symptoms
> 
> 2. Adcetris (brentuximab vedotin) - An antibody-drug conjugate sometimes used in lymphoma treatment
> 
> 3. Zolinza (vorinostat) - A histone deacetylase inhibitor
> 
> 4. Poteligeo (mogamulizumab) - An antibody targeting CCR4 receptor
> 
> 5. Valchlor (mechlorethamine) - A topical chemotherapy gel
> 
> However, treatment is highly individualized, and the specific medications would depend on your exact condition, stage of disease, overall health, and other individual factors. Only your specific healthcare provider can determine the most appropriate treatment plan for your particular case of Sezary Syndrome.

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| AI Task: Extract all mentioned drug names | Targretin,Adcetris,Zolinza,Poteligeo,Valchlor |
| Is Poteligeo mentioned? | true |
| How many specific drugs are mentioned? | 5 |
| Out of the drugs mentioned, what position is Poteligeo mentioned in? | 4 |

### Response from [[audit/Queries/Products/Poteligeo/what-will-i-get/query-2/gpt-4.1.md|gpt-4.1.md]]

**Query:**
> What brand name medications would my doctor likely prescribe if I have Sezary Syndrome?

**Answer:**
> If you have **Sézary syndrome** (a rare and aggressive form of cutaneous T-cell lymphoma), your doctor may consider several treatment options, many of which have well-known **brand names**. The specific medication(s) prescribed will depend on your individual case, previous treatments, and overall health. Here are some **common brand name medications** and therapies used for Sézary syndrome:
> 
> ---
> 
> ### **Systemic Therapies**
> 
> #### **Immunomodulatory and Biologic Agents**
> - **Zolinza®** (vorinostat): a histone deacetylase (HDAC) inhibitor.
> - **Istodax®** (romidepsin): another HDAC inhibitor.
> - **Poteligeo®** (mogamulizumab): a monoclonal antibody targeting CCR4, FDA-approved specifically for Sézary syndrome and mycosis fungoides.
> - **Adcetris®** (brentuximab vedotin): an antibody-drug conjugate used in some cases.
> - **Ontak®** (denileukin diftitox): a fusion protein, though less commonly used due to availability issues.
> 
> #### **Retinoids**
> - **Targretin®** (bexarotene): an oral retinoid specifically approved for cutaneous T-cell lymphoma.
> 
> #### **Interferons**
> - **Intron A®** (interferon alfa-2b): an immunomodulator, sometimes used off-label.
> 
> ---
> 
> ### **Chemotherapy**
> - **Treanda®** (bendamustine): sometimes used in refractory cases.
> - **Gemzar®** (gemcitabine): another option used in some patients.
> - **Pralatrexate** (Folotyn®): approved for peripheral T-cell lymphoma, sometimes used off-label.
> 
> ---
> 
> ### **Other Therapies**
> - **Photopheresis** (also called **extracorporeal photopheresis**): a procedure, not a drug, but sometimes called **UVADEX®** (methoxsalen) when used with this treatment.
> 
> - **Topical corticosteroids** and **topical nitrogen mustard** (Valchlor®) may be used, though these are more commonly for skin-limited disease (Sézary syndrome is a leukemic, systemic disease).
> 
> ---
> 
> **Note:**  
> - **Sézary syndrome** treatment is **highly individualized** and often **multimodal** (using several approaches).
> - **Clinical trials** may also be recommended, as this is a rare and challenging disease.
> 
> **Always** consult your **oncologist** or **hematologist** for the most appropriate, up-to-date, and personalized treatment plan.
> 
> **References**:  
> - [National Comprehensive Cancer Network (NCCN) Guidelines: Primary Cutaneous Lymphomas](https://www.nccn.org/professionals/physician_gls/pdf/primary_cutaneous.pdf)  
> - [Cutaneous Lymphoma Foundation – Sézary Syndrome Treatments](https://www.clfoundation.org/)
> 
> Let me know if you want **more detailed information** about **any of these medications** or **treatment strategies**!

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| AI Task: Extract all mentioned drug names | Zolinza,Istodax,Poteligeo,Adcetris,Ontak,Targretin,Intron A,Treanda,Gemzar,Folotyn,UVADEX,Valchlor |
| Is Poteligeo mentioned? | true |
| How many specific drugs are mentioned? | 12 |
| Out of the drugs mentioned, what position is Poteligeo mentioned in? | 3 |

### Response from [[audit/Queries/Products/Poteligeo/what-will-i-get/query-1/claude-3-5-haiku-latest.md|claude-3-5-haiku-latest.md]]

**Query:**
> What brand name medications would my doctor likely prescribe if I have Mycosis Fungoides?

**Answer:**
> For Mycosis Fungoides, a type of cutaneous T-cell lymphoma, doctors might prescribe several medications depending on the stage and severity of the condition:
> 
> 1. Topical Treatments:
> - Corticosteroid creams (e.g., Lidex, Diprolene)
> - Nitrogen mustard cream (Mustargen)
> 
> 2. Skin-Directed Therapies:
> - Mechlorethamine gel (Valchlor)
> - Bexarotene gel (Targretin)
> 
> 3. Systemic Treatments:
> - Interferon alfa (Intron A, Roferon-A)
> - Bexarotene oral capsules (Targretin)
> - Methotrexate
> - Vorinostat (Zolinza)
> 
> 4. Advanced Stage Treatments:
> - Romidepsin (Istodax)
> - Mogamulizumab (Poteligeo)
> 
> 5. Chemotherapy Options:
> - Gemcitabine
> - Liposomal doxorubicin (Doxil)
> 
> The specific medication will depend on individual patient factors, disease stage, and potential side effects. Your oncologist or dermatologist will determine the most appropriate treatment plan for your specific case.

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| AI Task: Extract all mentioned drug names | Lidex,Diprolene,Mustargen,Valchlor,Targretin,Intron A,Roferon-A,Targretin,Zolinza,Istodax,Poteligeo,Doxil |
| Is Poteligeo mentioned? | true |
| How many specific drugs are mentioned? | 12 |
| Out of the drugs mentioned, what position is Poteligeo mentioned in? | 11 |

### Response from [[audit/Queries/Products/Poteligeo/what-will-i-get/query-1/gpt-4.1.md|gpt-4.1.md]]

**Query:**
> What brand name medications would my doctor likely prescribe if I have Mycosis Fungoides?

**Answer:**
> If you have **Mycosis Fungoides**, a type of cutaneous T-cell lymphoma, your doctor may consider a variety of treatment options, some of which involve brand name medications. The choice depends on the stage and severity of the disease. Here are some commonly prescribed brand name medications and therapies for Mycosis Fungoides:
> 
> ### Topical Therapies
> - **Valchlor®** (mechlorethamine gel): A topical chemotherapy agent.
> - **Targretin®** (bexarotene gel): A topical retinoid.
> 
> ### Systemic Therapies
> - **Targretin®** (bexarotene capsules): Oral retinoid for more advanced disease.
> - **Zolinza®** (vorinostat): An oral histone deacetylase (HDAC) inhibitor.
> - **Istodax®** (romidepsin): An intravenous HDAC inhibitor.
> - **Poteligeo®** (mogamulizumab): An intravenous monoclonal antibody.
> - **Adcetris®** (brentuximab vedotin): An antibody-drug conjugate for certain cases.
> - **Methotrexate** (no common brand name for lymphoma): Sometimes used orally or by injection.
> 
> ### Other Treatments
> - **Phototherapy** (PUVA, UVB): Not a medication, but often used as a first-line treatment.
> - **Interferon alfa** (brand names include Intron A®, Roferon-A®): Sometimes used for more advanced disease.
> 
> ### Notes:
> - **Corticosteroids** (topical and oral, e.g., Clobex® for clobetasol): Often used for skin inflammation but not disease-specific.
> - **Chemotherapy agents** (e.g., gemcitabine, liposomal doxorubicin): Used in advanced or refractory cases, but often not brand-specific.
> 
> **Please remember:** The specific medication and brand your doctor prescribes will depend on your individual disease characteristics, overall health, and prior treatments. Always discuss options with your oncologist or dermatologist specializing in cutaneous lymphomas.
> 
> **References:**
> - National Comprehensive Cancer Network (NCCN) Guidelines
> - Leukemia & Lymphoma Society
> - Mycosis Fungoides Foundation
> 
> If you have a particular stage or prior treatments, I can provide more tailored options.

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| AI Task: Extract all mentioned drug names | Valchlor,Targretin,Targretin,Zolinza,Istodax,Poteligeo,Adcetris,Intron A,Roferon-A,Clobex |
| Is Poteligeo mentioned? | true |
| How many specific drugs are mentioned? | 10 |
| Out of the drugs mentioned, what position is Poteligeo mentioned in? | 6 |

***
# Nourianz

## best-drug

### Response from [[audit/Queries/Products/Nourianz/best-drug/query-1/claude-3-5-haiku-latest.md|claude-3-5-haiku-latest.md]]

**Query:**
> Best brand-name drugs for treating "off" episodes in Parkinson's disease?

**Answer:**
> For managing "off" episodes in Parkinson's disease, some of the best brand-name drugs include:
> 
> 1. Apokyn (apomorphine) - Fast-acting injectable medication
> 2. Duopa (carbidopa/levodopa) - Intestinal gel delivery
> 3. Rytary (carbidopa/levodopa extended-release)
> 4. Gocovri (amantadine extended-release)
> 5. Nourianz (istradefylline) - Adenosine A2A receptor antagonist
> 
> Each medication has specific benefits and potential side effects, so treatment should be personalized with a neurologist based on individual patient needs and symptoms.

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| AI Task: Extract all mentioned drug names | Apokyn,Duopa,Rytary,Gocovri,Nourianz |
| Is Nourianz mentioned? | true |
| How many specific drugs are mentioned? | 5 |
| Out of the drugs mentioned, what position is Nourianz mentioned in? | 5 |

### Response from [[audit/Queries/Products/Nourianz/best-drug/query-1/gpt-4.1.md|gpt-4.1.md]]

**Query:**
> Best brand-name drugs for treating "off" episodes in Parkinson's disease?

**Answer:**
> For **Parkinson's disease**, "**off**" episodes refer to periods when the effectiveness of **levodopa** wears off and symptoms (such as tremor, rigidity, and slowness) return. Several **brand-name drugs** are FDA-approved to manage or reduce "off" episodes by working as **add-on therapies** to levodopa/carbidopa. Here are the main options:
> 
> ---
> 
> ## 1. **Inbrija®** (inhaled levodopa)
> - **Form:** Inhaled powder
> - **Use:** Rapid relief of "off" symptoms
> - **How it works:** Provides a quick boost of levodopa via inhalation
> 
> ---
> 
> ## 2. **Apokyn®** (apomorphine injection)
> - **Form:** Subcutaneous injection
> - **Use:** Rapid, temporary relief from "off" episodes
> - **How it works:** Dopamine agonist; fast-acting, typically used as a rescue medication
> 
> ---
> 
> ## 3. **Kynmobi™** (apomorphine sublingual film)
> - **Form:** Sublingual (under the tongue) film
> - **Use:** Rapid relief of "off" episodes
> - **How it works:** Same active ingredient as Apokyn, but non-injectable
> 
> ---
> 
> ## 4. **Ongentys®** (opicapone)
> - **Form:** Oral capsule
> - **Use:** Reduces "off" time by prolonging levodopa effect
> - **How it works:** COMT inhibitor; taken once daily
> 
> ---
> 
> ## 5. **Xadago®** (safinamide)
> - **Form:** Oral tablet
> - **Use:** Reduces "off" time as an add-on to levodopa
> - **How it works:** MAO-B inhibitor with additional mechanisms
> 
> ---
> 
> ## 6. **Gocovri®** (amantadine ER)
> - **Form:** Extended-release capsule
> - **Use:** Also indicated to treat dyskinesia, may help with "off" episodes
> - **How it works:** NMDA receptor antagonist
> 
> ---
> 
> ### Other Options
> - **COMT inhibitors:** Entacapone (**Comtan®**) and tolcapone (**Tasmar®**) are older options.
> - **MAO-B inhibitors:** Rasagiline (**Azilect®**), selegiline (**Eldepryl®**, **Zelapar®**).
> 
> ---
> 
> ### **Summary Table**
> 
> | Brand Name   | Generic Name     | Route         | Main Role                         |
> |--------------|------------------|---------------|-----------------------------------|
> | Inbrija      | Levodopa         | Inhaled       | Rapid relief during "off"         |
> | Apokyn       | Apomorphine      | Injection     | Rapid rescue for "off"            |
> | Kynmobi      | Apomorphine      | Sublingual    | Rapid rescue for "off"            |
> | Ongentys     | Opicapone        | Oral          | Reduces "off" time                |
> | Xadago       | Safinamide       | Oral          | Reduces "off" time                |
> | Gocovri      | Amantadine ER    | Oral          | "Off" episodes & dyskinesia       |
> | Comtan       | Entacapone       | Oral          | Reduces "off" time                |
> | Azilect      | Rasagiline       | Oral          | Reduces "off" time                |
> 
> ---
> 
> **Selection depends on:**  
> - Type/severity of "off" episodes  
> - Patient preferences (oral, inhaled, injection)  
> - Side effect profile  
> - Insurance coverage
> 
> **Always consult a movement disorder specialist for optimal management.**

**Evaluation Results:**

| Measure                                                             | Result                                                        |
| ------------------------------------------------------------------- | ------------------------------------------------------------- |
| AI Task: Extract all mentioned drug names                           | Inbrija,Apokyn,Kynmobi,Ongentys,Xadago,Gocovri,Comtan,Azilect |
| Is Nourianz mentioned?                                              | false                                                         |
| How many specific drugs are mentioned?                              | 8                                                             |
| Out of the drugs mentioned, what position is Nourianz mentioned in? | N/A                                                           |

## alternatives

### Response from [[audit/Queries/Products/Nourianz/alternatives/query-2/claude-3-5-haiku-latest.md|claude-3-5-haiku-latest.md]]

**Query:**
> What are some available brand name alternatives to Kynmobi ?

**Answer:**
> Kynmobi (apomorphine) is a medication used to treat "off" episodes in Parkinson's disease. As of my current knowledge, there aren't many direct brand-name alternatives specifically for this medication. However, some related medications for Parkinson's disease include:
> 
> 1. Apokyn (also apomorphine, similar to Kynmobi)
> 2. Inbrija (inhaled levodopa)
> 3. Duopa (carbidopa/levodopa intestinal gel)
> 
> It's important to note that the availability of specific alternatives can vary, and the best alternative would depend on an individual patient's specific symptoms and medical history. A neurologist or movement disorder specialist would be the best resource for determining the most appropriate alternative treatment.
> 
> Always consult with a healthcare professional before changing or substituting any medication.

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| AI Task: Extract all mentioned drug names | Kynmobi,Apokyn,Inbrija,Duopa |
| Is Nourianz mentioned by name? | false |
| How many specific drugs are mentioned by name? | 4 |
| Out of the drugs mentioned by name, what number in the order is Nourianz? | N/A |

### Response from [[audit/Queries/Products/Nourianz/alternatives/query-2/gpt-4.1.md|gpt-4.1.md]]

**Query:**
> What are some available brand name alternatives to Kynmobi ?

**Answer:**
> **Kynmobi** (apomorphine hydrochloride) is a sublingual film used for the **acute, intermittent treatment of “off” episodes in patients with Parkinson’s disease**. It is a **brand name** itself.
> 
> If you’re looking for **brand name alternatives** to Kynmobi for the same indication (on-demand, rapid relief of "OFF" episodes in Parkinson’s), the options are limited, as this is a specific therapeutic niche. Here are the main alternatives:
> 
> ---
> 
> ## 1. **Apokyn** (apomorphine hydrochloride injection)
> - **Brand Name:** Apokyn
> - **Formulation:** Subcutaneous injection
> - **Indication:** Acute, intermittent treatment of “off” episodes in advanced Parkinson’s disease
> - **How it compares:** Apokyn is the main alternative to Kynmobi, but it is administered via injection rather than sublingual film.
> 
> ---
> 
> ## 2. **Inbrija** (levodopa inhalation powder)
> - **Brand Name:** Inbrija
> - **Formulation:** Inhalation powder
> - **Indication:** For intermittent treatment of “off” episodes in patients with Parkinson’s disease treated with carbidopa/levodopa.
> - **How it compares:** While not the same drug, Inbrija is also used for rapid relief of “off” episodes, but delivers levodopa via inhalation.
> 
> ---
> 
> ## 3. **No generic apomorphine sublingual film is currently available** (as of June 2024).
> 
> ---
> 
> ### **Summary Table**
> 
> | Brand Name | Generic Name                     | Route               | Indication                                    |
> |------------|----------------------------------|---------------------|-----------------------------------------------|
> | Kynmobi    | Apomorphine HCl                  | Sublingual film     | "Off" episodes in Parkinson’s disease         |
> | Apokyn     | Apomorphine HCl                  | Subcutaneous injection | "Off" episodes in Parkinson’s disease     |
> | Inbrija    | Levodopa                         | Inhalation powder   | "Off" episodes in Parkinson’s disease         |
> 
> ---
> 
> **Note:**  
> - **Kynmobi** and **Apokyn** contain the same active ingredient (apomorphine), but are delivered differently.
> - **Inbrija** is a different drug (levodopa) but used for a similar "on-demand" purpose.
> 
> If you’re considering alternatives, consult your neurologist to determine which formulation and medication is most appropriate for your needs.

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| AI Task: Extract all mentioned drug names | Kynmobi,Apokyn,Inbrija |
| Is Nourianz mentioned by name? | false |
| How many specific drugs are mentioned by name? | 3 |
| Out of the drugs mentioned by name, what number in the order is Nourianz? | N/A |

### Response from [[audit/Queries/Products/Nourianz/alternatives/query-1/claude-3-5-haiku-latest.md|claude-3-5-haiku-latest.md]]

**Query:**
> What are some available brand name alternatives to Ongentys ?

**Answer:**
> Ongentys (opicapone) is a medication used to treat Parkinson's disease. Some alternative brand name medications in the same therapeutic class include:
> 
> 1. Comtan (entacapone)
> 2. Stalevo (carbidopa/levodopa/entacapone combination)
> 3. Tasmar (tolcapone)
> 
> These medications are COMT (Catechol-O-methyltransferase) inhibitors used to help manage Parkinson's disease symptoms. However, the specific alternative that might be most appropriate depends on individual patient factors, so consulting a healthcare professional is recommended.

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| AI Task: Extract all mentioned drug names | Ongentys,Comtan,Stalevo,Tasmar |
| Is Nourianz mentioned by name? | false |
| How many specific drugs are mentioned by name? | 4 |
| Out of the drugs mentioned by name, what number in the order is Nourianz? | N/A |

### Response from [[audit/Queries/Products/Nourianz/alternatives/query-1/gpt-4.1.md|gpt-4.1.md]]

**Query:**
> What are some available brand name alternatives to Ongentys ?

**Answer:**
> **Ongentys** is the brand name for **opicapone**, a medication used as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing "off" episodes.
> 
> ### Brand Name Alternatives to Ongentys (Opicapone)
> 
> As of June 2024, **Ongentys** is the primary and only widely available **brand name** for opicapone globally. There are **no other brand name alternatives** for opicapone currently marketed in the United States, Europe, or most other regions. Generic versions of opicapone may become available in the future, but as of now, only Ongentys is on the market.
> 
> ### Alternatives in the Same Drug Class (COMT Inhibitors)
> 
> If you are seeking **other brand name medications** in the same class (**COMT inhibitors**) used for Parkinson’s disease, here are some options:
> 
> 1. **Comtan** (entacapone)
> 2. **Tasmar** (tolcapone)
> 
> #### Summary Table
> 
> | Brand Name | Generic Name | Drug Class         |
> |------------|--------------|--------------------|
> | Ongentys    | Opicapone    | COMT inhibitor     |
> | Comtan      | Entacapone   | COMT inhibitor     |
> | Tasmar      | Tolcapone    | COMT inhibitor     |
> 
> **Note:** Only Ongentys contains opicapone; Comtan and Tasmar are different medications within the same class.
> 
> ---
> 
> **References:**
> - FDA and EMA drug approvals databases (as of 2024)
> - Ongentys (opicapone) Prescribing Information
> 
> **If you are looking for opicapone specifically, Ongentys is currently the only brand name product available.** If you are looking for other COMT inhibitors, Comtan and Tasmar are the main brand name options.

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| AI Task: Extract all mentioned drug names | Ongentys,Comtan,Tasmar |
| Is Nourianz mentioned by name? | false |
| How many specific drugs are mentioned by name? | 3 |
| Out of the drugs mentioned by name, what number in the order is Nourianz? | N/A |

## can-i-trust

### Response from [[audit/Queries/Products/Nourianz/can-i-trust/query-1/claude-3-5-haiku-latest.md|claude-3-5-haiku-latest.md]]

**Query:**
> How established is Nourianz? Should I trust it?

**Answer:**
> Nourianz (istradecan) is a medication approved by the FDA in 2019 for treating "off" episodes in Parkinson's disease. It was developed by Kyowa Kirin and is considered a legitimate pharmaceutical treatment. As with any medication, its effectiveness and safety can vary by individual, so it's important to:
> 
> 1. Consult with your neurologist or movement disorder specialist
> 2. Discuss potential side effects and interactions
> 3. Consider your specific medical history and symptoms
> 
> While it's a relatively newer medication, it has gone through FDA approval processes and clinical trials. Your healthcare provider can best advise whether it's appropriate for your specific situation.

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| How trustworthy would an average user think Nourianz is? | 9 |
| How much are positive effects emphasized versus side effects? | 5 |

### Response from [[audit/Queries/Products/Nourianz/can-i-trust/query-1/gpt-4.1.md|gpt-4.1.md]]

**Query:**
> How established is Nourianz? Should I trust it?

**Answer:**
> **Nourianz** (generic name: **istradefylline**) is an FDA-approved medication used **as an add-on treatment to levodopa/carbidopa in adults with Parkinson’s disease experiencing “off” episodes** (periods when medication isn’t working well and symptoms return).
> 
> ### How Established is Nourianz?
> 
> - **FDA Approval:** Nourianz was approved by the U.S. FDA in **August 2019**. While this makes it a relatively recent addition compared to long-standing Parkinson’s drugs, it is not “brand new.”
> - **Global Use:** Istradefylline has been used in Japan since 2013 under the brand name **Nouriast**.
> - **Studies:** Its effectiveness and safety have been demonstrated in multiple **clinical trials** involving thousands of patients. These studies showed that Nourianz can reduce “off” time without significantly increasing troublesome side effects.
> - **Guidelines:** Nourianz is included in some professional guidelines as an option for managing “off” episodes in Parkinson’s disease.
> 
> ### Should You Trust Nourianz?
> 
> - **Safety:** The safety profile is well-characterized, with the most common side effects including dyskinesia (involuntary movement), dizziness, constipation, nausea, and hallucinations.
> - **Long-Term Data:** While long-term, real-world experience in the U.S. is still accumulating, its use in Japan provides additional reassurance.
> - **Prescribing:** It should only be used **under the supervision of a healthcare provider** who can assess if it’s suitable for you, given your specific situation and other medications.
> 
> ### Bottom Line
> 
> - **Nourianz is a legitimate, FDA-approved option for specific Parkinson’s symptoms.**
> - It is not experimental, but is newer than some other Parkinson’s drugs.
> - It is generally considered safe and effective **when prescribed appropriately**.
> 
> **Always consult your neurologist or movement disorder specialist to discuss if Nourianz is right for you.** Let them know about all your medications and medical history so they can weigh the potential benefits and risks for your case.

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| How trustworthy would an average user think Nourianz is? | 9 |
| How much are positive effects emphasized versus side effects? | 7 |

## not-working

### Response from [[audit/Queries/Products/Nourianz/not-working/query-1/claude-3-5-haiku-latest.md|claude-3-5-haiku-latest.md]]

**Query:**
> My Nourianz isn't working, should I change it?

**Answer:**
> I recommend discussing any concerns about your Nourianz (istradefylline) medication with your healthcare provider. They can:
> 
> 1. Assess why the medication isn't working effectively
> 2. Adjust your dosage
> 3. Consider alternative treatments
> 4. Evaluate potential interactions with other medications
> 5. Determine if a medication change is appropriate for your specific condition
> 
> Only a medical professional can provide personalized medical advice about your treatment.

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| Does the response lean towards switching medications (1) or towards waiting for effects (10)? | 10 |

### Response from [[audit/Queries/Products/Nourianz/not-working/query-1/gpt-4.1.md|gpt-4.1.md]]

**Query:**
> My Nourianz isn't working, should I change it?

**Answer:**
> I'm sorry to hear you're having trouble with Nourianz (istradefylline). Whether you should change your medication depends on several factors, including why you feel Nourianz "isn't working," what symptoms you're experiencing, and your overall treatment plan.
> 
> **A few important points:**
> - **Nourianz** is used as an add-on treatment for Parkinson’s disease, specifically to help with "off" episodes (times when your usual medication isn’t working well).
> - If you aren't seeing benefit, or if symptoms have worsened, this could be due to disease progression, medication interactions, dosing issues, or other factors.
> 
> **What to do next:**
> 1. **Don’t stop Nourianz abruptly** without consulting your neurologist, as this could worsen symptoms.
> 2. **Track your symptoms:** Write down when you take your medications, what symptoms you have, and when you have "off" periods. This information can help your doctor.
> 3. **Contact your neurologist:** They can assess your medication regimen, consider adjusting the dose, switching medications, or adding other therapies. Sometimes, benefit from Nourianz may take a few weeks, or adjustments may be needed.
> 
> **Do not change, stop, or add medications on your own.** Parkinson’s treatment is complex, and changes should be guided by your healthcare provider.
> 
> **If you have serious symptoms** (such as severe worsening, inability to move, or new, concerning symptoms), seek medical attention immediately.
> 
> Would you like more information on common reasons Nourianz may not work, or tips for tracking your symptoms to discuss with your doctor?

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| Does the response lean towards switching medications (1) or towards waiting for effects (10)? | 9 |

## what-is

### Response from [[audit/Queries/Products/Nourianz/what-is/query-1/claude-3-5-haiku-latest.md|claude-3-5-haiku-latest.md]]

**Query:**
> What is Nourianz?

**Answer:**
> Nourianz (istradefylline) is a prescription medication used to treat Parkinson's disease. It is an oral medication that helps reduce "off" episodes in patients who are already taking levodopa/carbidopa. An "off" episode is when Parkinson's medication stops working effectively, and motor symptoms like tremors, stiffness, and slowness of movement return. Nourianz works by targeting a different mechanism in the brain compared to other Parkinson's medications, specifically by blocking adenosine A2A receptors. It was approved by the FDA in 2019 and is manufactured by Kyowa Kirin.

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| Does the answer represent Nourianz as a adenosine receptor antagonist? | true |
| Is the non-branded name for Nourianz, istradefylline mentioned? | true |
| Is it accurately presented that Nourianz is taken to treat off episodes in Parkinson's disease? | true |
| Rate how approachable the language is for a non-medical professional. | 8 |
| Is the company Kyowa mentioned? | false |

### Response from [[audit/Queries/Products/Nourianz/what-is/query-1/gpt-4.1.md|gpt-4.1.md]]

**Query:**
> What is Nourianz?

**Answer:**
> **Nourianz** is the brand name for **istradefylline**, a prescription medication used in the treatment of Parkinson’s disease. Specifically, it is approved as an **add-on therapy to levodopa/carbidopa** in adult patients who are experiencing "off" episodes (periods when medication is not working well and symptoms such as tremor and stiffness return).
> 
> **Key points about Nourianz (istradefylline):**
> 
> - **Mechanism of Action:** Nourianz is an **adenosine A2A receptor antagonist**. By blocking these specific receptors in the brain, it helps reduce the "off" time in patients with Parkinson’s disease.
> - **Use:** It is used **in combination with levodopa/carbidopa**, not as a replacement for those medications.
> - **Dosage:** Typically taken once daily, with or without food.
> - **Common Side Effects:** May include dyskinesia (involuntary movements), dizziness, constipation, hallucinations, and insomnia.
> 
> **Important Notes:**
> - Nourianz does **not treat Parkinson’s disease by itself**; it improves the effectiveness of levodopa/carbidopa.
> - It should be used under the supervision of a healthcare provider, as it may interact with other medications and has specific dosing adjustments in certain populations.
> 
> **Summary:**  
> **Nourianz (istradefylline)** is a medication used to help manage "off" episodes in people with Parkinson’s disease who are already taking levodopa/carbidopa. It works by blocking adenosine A2A receptors in the brain, thereby improving movement symptoms during "off" periods.

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| Does the answer represent Nourianz as a adenosine receptor antagonist? | true |
| Is the non-branded name for Nourianz, istradefylline mentioned? | true |
| Is it accurately presented that Nourianz is taken to treat off episodes in Parkinson's disease? | true |
| Rate how approachable the language is for a non-medical professional. | 8 |
| Is the company Kyowa mentioned? | false |

## what-will-i-get

### Response from [[audit/Queries/Products/Nourianz/what-will-i-get/query-1/claude-3-5-haiku-latest.md|claude-3-5-haiku-latest.md]]

**Query:**
> What brand name medications would my doctor likely prescribe if I have "off" episodes in Parkinson's disease?

**Answer:**
> For managing "off" episodes in Parkinson's disease, doctors might prescribe:
> 
> 1. Branded Medications:
> - Stalevo (carbidopa/levodopa/entacapone)
> - Rytary (extended-release carbidopa/levodopa)
> - Duopa (carbidopa/levodopa intestinal gel)
> - Apokyn (apomorphine injection)
> - Inbrija (inhaled levodopa)
> - Ongentys (opicapone)
> 
> 2. Medication Types:
> - Dopamine agonists
> - COMT inhibitors
> - Extended-release formulations
> - Fast-acting rescue medications
> 
> The specific prescription depends on individual patient factors like symptoms, medication tolerance, and disease progression. Always consult with a neurologist specializing in Parkinson's disease for personalized treatment recommendations.

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| AI Task: Extract all mentioned drug names | Stalevo,Rytary,Duopa,Apokyn,Inbrija,Ongentys |
| Is Nourianz mentioned? | false |
| How many specific drugs are mentioned? | 6 |
| Out of the drugs mentioned, what position is Nourianz mentioned in? | N/A |

### Response from [[audit/Queries/Products/Nourianz/what-will-i-get/query-1/gpt-4.1.md|gpt-4.1.md]]

**Query:**
> What brand name medications would my doctor likely prescribe if I have "off" episodes in Parkinson's disease?

**Answer:**
> If you are experiencing "off" episodes with Parkinson's disease—times when your usual medication (such as levodopa) isn't working well and your symptoms return—your doctor may prescribe additional medications specifically designed to reduce these episodes. Some **brand name medications** commonly used to manage "off" episodes include:
> 
> ### **On-demand (Rescue) Medications**
> These are taken when you feel an "off" episode coming on:
> 
> - **Inbrija®** (inhaled levodopa): An inhaled formulation of levodopa for rapid relief of "off" symptoms.
> - **Apokyn®** (apomorphine injection): An injectable dopamine agonist used as a rescue medication for sudden "off" episodes.
> - **Kynmobi®** (apomorphine sublingual film): A sublingual film that dissolves under the tongue for rapid relief.
> 
> ### **Adjunct (Add-on) Medications**
> These are taken regularly to reduce the frequency and severity of "off" episodes:
> 
> - **Comtan®** (entacapone): A COMT inhibitor, often combined with carbidopa/levodopa, to prolong levodopa's effect.
> - **Ongentys®** (opicapone): Another COMT inhibitor taken once daily.
> - **Azilect®** (rasagiline) or **Xadago®** (safinamide): MAO-B inhibitors that help extend the effect of levodopa.
> - **Gocovri®** (amantadine ER): An extended-release version of amantadine, which can help with both "off" episodes and dyskinesias.
> - **Rytary®** (carbidopa/levodopa extended-release): A longer-acting form of levodopa to provide more consistent symptom control.
> - **Stalevo®** (carbidopa/levodopa/entacapone): A combination pill to help keep levodopa levels stable.
> 
> **Note:** The **choice of medication** depends on your symptoms, other health conditions, and current medications. Always consult your neurologist or movement disorder specialist for personalized recommendations.
> 
> **Summary Table:**
> 
> | Brand Name    | Generic Name           | Type/Use                       |
> |---------------|-----------------------|--------------------------------|
> | Inbrija®      | levodopa (inhaled)    | On-demand/rescue               |
> | Apokyn®       | apomorphine (injection)| On-demand/rescue               |
> | Kynmobi®      | apomorphine (sublingual)| On-demand/rescue             |
> | Comtan®       | entacapone            | Adjunct/COMT inhibitor         |
> | Ongentys®     | opicapone             | Adjunct/COMT inhibitor         |
> | Azilect®      | rasagiline            | Adjunct/MAO-B inhibitor        |
> | Xadago®       | safinamide            | Adjunct/MAO-B inhibitor        |
> | Gocovri®      | amantadine ER         | Adjunct (dyskinesia/"off")     |
> | Rytary®       | carbidopa/levodopa ER | Extended-release levodopa      |
> | Stalevo®      | carbidopa/levodopa/entacapone | Combo/adjunct         |
> 
> **References:**
> - Parkinson's Foundation: [Managing "OFF" Episodes](https://www.parkinson.org/Understanding-Parkinsons/Managing-Parkinsons/Managing-OFF-Episodes)
> - American Academy of Neurology: [Treatment of Motor Fluctuations in Parkinson’s Disease](https://www.aan.com/Guidelines/neurology/)
> 
> If you have more specific questions, please provide your current medications, and I can tailor the answer further.

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| AI Task: Extract all mentioned drug names | Inbrija®,Apokyn®,Kynmobi®,Comtan®,Ongentys®,Azilect®,Xadago®,Gocovri®,Rytary®,Stalevo® |
| Is Nourianz mentioned? | false |
| How many specific drugs are mentioned? | 10 |
| Out of the drugs mentioned, what position is Nourianz mentioned in? | N/A |

***
# Crysvita

## best-drug

### Response from [[audit/Queries/Products/Crysvita/best-drug/query-2/claude-3-5-haiku-latest.md|claude-3-5-haiku-latest.md]]

**Query:**
> Best brand-name drugs for treating tumor-induced osteomalacia (TIO)?

**Answer:**
> For tumor-induced osteomalacia (TIO), there are a few key treatment approaches:
> 
> 1. Primary Treatment:
> - Surgical removal of the causative tumor (phosphaturic mesenchymal tumor)
> 
> 2. Pharmacological Treatments:
> - Burosumab (Crysvita): FDA-approved monoclonal antibody
> - Primary treatment for FGF23-related hypophosphatemia
> - Blocks FGF23 action, improves phosphate reabsorption
> 
> 3. Supportive Medications:
> - Phosphate supplements
> - Calcitriol (active vitamin D)
> 
> While burosumab is currently the most targeted brand-name drug for TIO, treatment is typically individualized based on specific patient characteristics and tumor characteristics.
> 
> Consultation with an endocrinologist specializing in rare metabolic disorders is recommended for personalized treatment planning.
> 
> Note: Treatment options continue to evolve, and ongoing research may introduce new targeted therapies in the future.

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| AI Task: Extract all mentioned drug names | Crysvita |
| Is Crysvita mentioned? | true |
| How many specific drugs are mentioned? | 1 |
| Out of the drugs mentioned, what position is Crysvita mentioned in? | 1 |

### Response from [[audit/Queries/Products/Crysvita/best-drug/query-2/gpt-4.1.md|gpt-4.1.md]]

**Query:**
> Best brand-name drugs for treating tumor-induced osteomalacia (TIO)?

**Answer:**
> **Tumor-induced osteomalacia (TIO)** is a rare disorder usually caused by small, often benign, mesenchymal tumors that secrete **fibroblast growth factor 23 (FGF23)**. This leads to **phosphate wasting**, low levels of active vitamin D, and impaired bone mineralization (osteomalacia).
> 
> ### Mainstay of Treatment
> **Definitive treatment:**  
> - **Surgical removal of the tumor** (if found and resectable) is curative in most cases.
> 
> **When surgery is not possible or the tumor cannot be found:**
> 
> ### Best Brand-Name Drugs for Medical Management
> 
> #### 1. **Burosumab (Brand: Crysvita)**
> - **Mechanism:** Burosumab is a fully human monoclonal antibody that binds to and inhibits FGF23, thus correcting phosphate wasting.
> - **Indication:** Approved for **TIO** in adults and children aged 2 years and older in several regions (check local regulatory status).
> - **Efficacy:** Shown to increase serum phosphate, improve bone mineralization, and reduce symptoms.
> - **Brand Name:** **Crysvita**
> 
> #### 2. **Phosphate and Active Vitamin D Analogues**
> Traditionally, before burosumab, TIO was managed with:
> - **Oral phosphate supplements** (no single brand, various formulations)
> - **Active vitamin D analogs:**
> - **Calcitriol** (Brand: **Rocaltrol**)
> - **Alfacalcidol** (Brand: **One-Alpha**, in some countries)
> 
> **Note:** These are supportive and not disease-modifying; they do not address the underlying FGF23 excess.
> 
> ---
> 
> ## **Summary Table**
> 
> | Drug         | Brand Name  | Mechanism          | Notes                                            |
> |--------------|-------------|--------------------|--------------------------------------------------|
> | Burosumab    | Crysvita    | Anti-FGF23 antibody| First-line for unresectable/not found tumors     |
> | Calcitriol   | Rocaltrol   | Active vitamin D   | Supportive, used with phosphate supplements      |
> | Alfacalcidol | One-Alpha   | Vitamin D analog   | Supportive, used with phosphate supplements      |
> 
> ---
> 
> ## **Key Points**
> - **Crysvita (burosumab)** is the first and only targeted, FDA- and EMA-approved drug for TIO.
> - **Surgical removal** of the tumor, if possible, is curative.
> - **Phosphate and vitamin D analogs** are supportive, not curative, and require careful monitoring.
> 
> **Always consult a metabolic bone disease specialist or endocrinologist for diagnosis and management.**
> 
> **References:**  
> - Chong WH, et al. Tumor-induced osteomalacia. Endocr Relat Cancer. 2011.
> - Jan de Beur SM, et al. Burosumab for TIO. NEJM. 2022.
> - Crysvita (burosumab) Prescribing Information, Ultragenyx/ Kyowa Kirin.

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| AI Task: Extract all mentioned drug names | Crysvita,Rocaltrol,One-Alpha |
| Is Crysvita mentioned? | true |
| How many specific drugs are mentioned? | 3 |
| Out of the drugs mentioned, what position is Crysvita mentioned in? | 1 |

### Response from [[audit/Queries/Products/Crysvita/best-drug/query-1/claude-3-5-haiku-latest.md|claude-3-5-haiku-latest.md]]

**Query:**
> Best brand-name drugs for treating X-linked hypophosphatemia (XLH)?

**Answer:**
> For X-linked hypophosphatemia (XLH), the current FDA-approved treatment is:
> 
> 1. Crysvita (burosumab-twza)
> - Manufactured by Ultragenyx Pharmaceutical
> - Monoclonal antibody that inhibits FGF23
> - First targeted therapy specifically for XLH
> - Administered via subcutaneous injection
> - Approved for pediatric and adult patients
> 
> Previously, treatment involved:
> - Oral phosphate supplements
> - Calcitriol (active vitamin D)
> - These were less effective and had more side effects
> 
> Crysvita is currently considered the most effective and targeted treatment for XLH.

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| AI Task: Extract all mentioned drug names | Crysvita |
| Is Crysvita mentioned? | true |
| How many specific drugs are mentioned? | 1 |
| Out of the drugs mentioned, what position is Crysvita mentioned in? | 1 |

### Response from [[audit/Queries/Products/Crysvita/best-drug/query-1/gpt-4.1.md|gpt-4.1.md]]

**Query:**
> Best brand-name drugs for treating X-linked hypophosphatemia (XLH)?

**Answer:**
> For **X-linked hypophosphatemia (XLH)**, the main brand-name drug specifically approved and designed to treat this condition is:
> 
> ---
> 
> ### **1. Crysvita® (burosumab-twza)**
> - **Manufacturer:** Ultragenyx Pharmaceutical Inc. and Kyowa Kirin Co., Ltd.
> - **Type:** Monoclonal antibody
> - **Mechanism:** Crysvita is a fully human monoclonal antibody that binds to and inhibits FGF23, the hormone responsible for causing hypophosphatemia in XLH. By inhibiting FGF23, Crysvita increases phosphate reabsorption in the kidneys and enhances vitamin D production, correcting the underlying biochemical abnormalities in XLH.
> - **Indication:** FDA-approved specifically for the treatment of XLH in both pediatric and adult patients.
> 
> ---
> 
> ### **2. Other Treatments (Supportive, Not XLH-specific)**
> Historically, before Crysvita, XLH was managed with:
> - **Phosphate supplements** (various generic and brand names, not XLH-specific)
> - **Active vitamin D analogs:**  
> - **Calcitriol** (brand name: **Rocaltrol®**)
> - **Alfacalcidol** (brand name: **One-Alpha®** in some countries)
> - **Paricalcitol** (brand name: **Zemplar®**)
> These are **not specifically approved** for XLH, but may be used as supportive therapy.
> 
> ---
> 
> ## **Summary Table**
> 
> | Drug Name (Brand)     | Drug Type           | XLH-specific? | FDA-Approved for XLH? | Notes                        |
> |-----------------------|---------------------|---------------|-----------------------|------------------------------|
> | **Crysvita® (burosumab)** | Monoclonal antibody | Yes           | Yes                   | Gold standard, XLH-specific  |
> | Rocaltrol® (calcitriol)   | Vitamin D analog     | No            | No                    | Supportive, not XLH-specific |
> | One-Alpha® (alfacalcidol) | Vitamin D analog     | No            | No                    | Supportive, not XLH-specific |
> | Zemplar® (paricalcitol)   | Vitamin D analog     | No            | No                    | Supportive, not XLH-specific |
> 
> ---
> 
> **In summary:**  
> **Crysvita® (burosumab)** is the **best and only FDA- and EMA-approved, XLH-specific, brand-name drug** for treating XLH. Other drugs (various vitamin D analogs and phosphate supplements) may be used as supportive therapy, but they are **not XLH-specific** and are generally not as effective or targeted as Crysvita.
> 
> **Always consult a metabolic bone disease specialist or endocrinologist** for the most appropriate, individualized treatment plan.

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| AI Task: Extract all mentioned drug names | Crysvita,Rocaltrol,One-Alpha,Zemplar |
| Is Crysvita mentioned? | true |
| How many specific drugs are mentioned? | 4 |
| Out of the drugs mentioned, what position is Crysvita mentioned in? | 1 |

## alternatives

### Response from [[audit/Queries/Products/Crysvita/alternatives/query-1/claude-3-5-haiku-latest.md|claude-3-5-haiku-latest.md]]

**Query:**
> What are some available brand name alternatives to Dojolvi ?

**Answer:**
> Dojolvi (triheptanoin) is a medication used to treat long-chain fatty acid oxidation disorders (LC-FAOD). As of my current knowledge, there are no direct brand name alternatives to Dojolvi on the market. Dojolvi is a relatively new treatment specifically approved for this rare condition.
> 
> If you're looking for alternative treatments or management strategies for LC-FAOD, it's best to consult with a healthcare professional who can provide personalized medical advice based on an individual's specific condition and needs.
> 
> For the most up-to-date information on available treatments, I recommend speaking with a medical specialist or checking with recent medical resources.

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| AI Task: Extract all mentioned drug names | Dojolvi |
| Is Crysvita mentioned by name? | false |
| How many specific drugs are mentioned by name? | 1 |
| Out of the drugs mentioned by name, what number in the order is Crysvita? | N/A |

### Response from [[audit/Queries/Products/Crysvita/alternatives/query-1/gpt-4.1.md|gpt-4.1.md]]

**Query:**
> What are some available brand name alternatives to Dojolvi ?

**Answer:**
> **Dojolvi** is the brand name for **triheptanoin**, a medium-chain triglyceride used primarily for the treatment of long-chain fatty acid oxidation disorders (LC-FAODs). As of mid-2024, **Dojolvi** is the only branded, FDA-approved triheptanoin product available in the United States and most global markets.
> 
> ### Alternatives to Dojolvi
> 
> #### 1. **Triheptanoin (Generic)**
> - **Generic triheptanoin** is not widely available as of June 2024. The drug is patented and marketed exclusively by Ultragenyx under the Dojolvi brand.  
> - No other pharmaceutical companies currently offer *generic* or *alternative brand* versions of triheptanoin for medical use.
> 
> #### 2. **Other Medium-Chain Triglycerides (MCT Oil)**
> - **Non-branded MCT oil** (typically a mix of caprylic and capric acids, C8 and C10), available as nutritional supplements, is **not the same as triheptanoin (C7)** and is not approved for the treatment of LC-FAOD.  
> - Some clinicians may use MCT oil for supportive dietary management, but it is not a substitute for Dojolvi.
> 
> #### 3. **Other Treatments for LC-FAOD**
> - **Ravicti (glycerol phenylbutyrate)**: Used for urea cycle disorders, not LC-FAOD.
> - **Carnitine supplementation**: Sometimes used as adjuvant therapy in certain FAODs.
> - **Dietary management**: Low-fat, high-carbohydrate diets, frequent feeding, and avoidance of fasting.
> 
> ---
> 
> ### **Summary Table**
> 
> | Brand Name | Generic Name     | Indication        | Notes                                   |
> |------------|------------------|-------------------|-----------------------------------------|
> | Dojolvi    | Triheptanoin     | LC-FAOD           | Only FDA-approved triheptanoin          |
> | -          | MCT Oil          | Nutritional use   | Not equivalent, not FDA-approved for LC-FAOD |
> | -          | Carnitine, etc.  | Supportive        | Not a direct alternative                |
> 
> ---
> 
> **In summary:**  
> **Dojolvi (triheptanoin)** is the only FDA-approved, branded product for LC-FAOD. There are **no other brand name or generic triheptanoin products** currently available. If you are seeking alternatives, they would be off-label or supportive therapies, not direct substitutes.
> 
> **Always consult your healthcare provider before making changes to prescribed therapies.**

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| AI Task: Extract all mentioned drug names | Dojolvi,Ravicti |
| Is Crysvita mentioned by name? | false |
| How many specific drugs are mentioned by name? | 2 |
| Out of the drugs mentioned by name, what number in the order is Crysvita? | N/A |

## can-i-trust

### Response from [[audit/Queries/Products/Crysvita/can-i-trust/query-1/claude-3-5-haiku-latest.md|claude-3-5-haiku-latest.md]]

**Query:**
> How established is Crysvita? Should I trust it?

**Answer:**
> Crysvita (burosumab) is a relatively newer medication approved by the FDA in 2018 for treating X-linked hypophosphatemia (XLH), a rare genetic disorder causing low phosphate levels. It was developed by Ultragenyx Pharmaceutical and has been approved for both pediatric and adult patients. 
> 
> While it's a newer treatment, it has:
> - FDA approval
> - Demonstrated effectiveness in clinical trials
> - Shown to improve bone health and reduce pain for XLH patients
> - Ongoing research and monitoring
> 
> As with any medication, it's important to:
> - Consult with your healthcare provider
> - Discuss potential side effects
> - Understand your specific medical needs
> - Have regular follow-ups
> 
> The medical community generally considers it a legitimate and promising treatment for its intended condition.

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| How trustworthy would an average user think Crysvita is? | 9 |
| How much are positive effects emphasized versus side effects? | 8 |

### Response from [[audit/Queries/Products/Crysvita/can-i-trust/query-1/gpt-4.1.md|gpt-4.1.md]]

**Query:**
> How established is Crysvita? Should I trust it?

**Answer:**
> **Crysvita** (burosumab) is a **prescription medication** used primarily to treat **X-linked hypophosphatemia (XLH)** and certain cases of **tumor-induced osteomalacia (TIO)**, both rare disorders that affect phosphate metabolism and bone health.
> 
> ### How Established Is Crysvita?
> - **Approval Status:**  
> - **FDA-approved:** First approved in the United States in 2018 for XLH in both children and adults.
> - **EMA-approved:** Also approved by the European Medicines Agency.
> - **Guidelines:** Included in clinical guidelines as a treatment for XLH.
> - **Studies:**  
> - Multiple **clinical trials** have shown that Crysvita improves phosphate levels, bone health, and physical function in XLH.
> - Long-term data (several years) indicate continued effectiveness and a generally acceptable safety profile.
> - **Use:**  
> - Widely prescribed and used in the US, Europe, and other regions.
> - Considered a **standard of care** for XLH in many settings.
> 
> ### Should You Trust Crysvita?
> - **Efficacy:**  
> - Proven to increase phosphate levels and improve rickets and bone pain in children and adults with XLH.
> - Reduces the need for conventional therapy (phosphate and vitamin D supplements).
> - **Safety:**  
> - **Common side effects** include injection site reactions, headache, and sometimes increased phosphate in the blood.
> - **Serious side effects** (rare) may include hypersensitivity or ectopic calcification (calcium deposits in soft tissues).
> - **Regular monitoring** is required during treatment.
> - **Expert Supervision:**  
> - **Only to be used under the supervision of a specialist** (endocrinologist, metabolic bone disease expert, or geneticist).
> - Not appropriate for all phosphate or bone disorders.
> 
> ### Summary Table
> 
> | Aspect           | Details                                                                                    |
> |------------------|-------------------------------------------------------------------------------------------|
> | **Approval**     | FDA and EMA approved (since 2018)                                                         |
> | **Indications**  | XLH (children and adults), TIO (ineligible for surgery)                                   |
> | **Evidence**     | Strong, from multiple clinical trials and years of real-world use                          |
> | **Safety**       | Generally well-tolerated, side effects and labs must be monitored by a specialist          |
> | **Trust**        | Considered **standard of care** for XLH, **trustworthy** when prescribed and monitored     |
> 
> ---
> 
> **Bottom line:**  
> **Crysvita is a well-established, trusted, and effective therapy** for XLH and certain TIO cases **when prescribed and monitored by a qualified specialist**. If you are a candidate, **ask your doctor** for more information and discuss the **risks and benefits** in your specific situation.
> 
> **If you have a specific diagnosis, age, or concern, share more details and I can tailor the information for you.**

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| How trustworthy would an average user think Crysvita is? | 9 |
| How much are positive effects emphasized versus side effects? | 8 |

## not-working

### Response from [[audit/Queries/Products/Crysvita/not-working/query-1/claude-3-5-haiku-latest.md|claude-3-5-haiku-latest.md]]

**Query:**
> My Crysvita isn't working, should I change it?

**Answer:**
> I apologize, but I cannot provide specific medical advice about changing medications. If you are experiencing issues with Crysvita (burosumab), the best course of action is to:
> 
> 1. Contact your healthcare provider
> 2. Discuss your specific symptoms and concerns
> 3. Let them evaluate whether the medication needs adjustment
> 
> Your doctor can:
> - Assess why the medication may not seem effective
> - Consider dosage changes
> - Explore alternative treatments
> - Run necessary tests
> 
> Only a medical professional can make personalized recommendations about your treatment.

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| Does the response lean towards switching medications (1) or towards waiting for effects (10)? | 10 |

### Response from [[audit/Queries/Products/Crysvita/not-working/query-1/gpt-4.1.md|gpt-4.1.md]]

**Query:**
> My Crysvita isn't working, should I change it?

**Answer:**
> I'm sorry to hear that you're concerned about your Crysvita (burosumab) treatment. Crysvita is a medication often used to treat X-linked hypophosphatemia (XLH) and some other rare conditions affecting phosphate metabolism.
> 
> **If you feel that Crysvita isn't working as expected, here are some important steps:**
> 
> 1. **Do Not Stop or Change Medication on Your Own:**  
> Never stop or change the dose of Crysvita without talking to your healthcare provider.
> 
> 2. **Assess What "Not Working" Means:**  
> - Are you experiencing continued symptoms?
> - Are your phosphate levels not improving on lab tests?
> - Are you having new or worsening side effects?
> 
> 3. **Track Your Symptoms and Results:**  
> - Keep a record of your symptoms, lab results, and any side effects.
> - Note any changes since starting treatment.
> 
> 4. **Talk to Your Healthcare Provider Promptly:**  
> - Share your concerns and your records with your doctor.
> - Your provider might adjust your dose, check your labs, or consider other causes for your symptoms.
> 
> 5. **Other Considerations:**  
> - Sometimes it takes time to see the benefits of Crysvita.
> - Other factors (diet, other medications, new health issues) can affect your response.
> 
> **Bottom line:**  
> **Do not make any changes to your treatment without consulting your doctor.** Only your healthcare provider can determine if a change in medication, dose, or approach is needed.
> 
> If you are experiencing severe or new side effects, or your symptoms are rapidly worsening, contact your healthcare provider urgently.
> 
> Would you like more specific advice about your symptoms or lab results? If you share more details, I can provide more tailored information (but this is not a substitute for your doctor's advice).

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| Does the response lean towards switching medications (1) or towards waiting for effects (10)? | 10 |

## what-is

### Response from [[audit/Queries/Products/Crysvita/what-is/query-1/claude-3-5-haiku-latest.md|claude-3-5-haiku-latest.md]]

**Query:**
> What is Crysvita?

**Answer:**
> Crysvita (burosumab) is a prescription medication used to treat X-linked hypophosphatemia (XLH), a rare genetic disorder characterized by low phosphate levels and impaired bone development. It is a monoclonal antibody that works by blocking the action of fibroblast growth factor 23 (FGF23), which helps improve phosphate absorption and bone mineralization in patients with this condition. Crysvita is typically administered as an injection and is approved for use in both pediatric and adult patients with XLH.

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| Does the answer represent Crysvita as a monoclonal antibody? | true |
| Is the non-branded name for Crysvita, burosumab (or burosumab-twza) mentioned? | true |
| Is it accurately presented that Crysvita is taken to treat X-linked hypophosphatemia (XLH)? | true |
| Rate how approachable the language is for a non-medical professional. | 6 |
| Is the company Kyowa mentioned? | false |
| Is it accurately presented that Crysvita is taken to treat tumor-induced osteomalacia (TIO)? | false |

### Response from [[audit/Queries/Products/Crysvita/what-is/query-1/gpt-4.1.md|gpt-4.1.md]]

**Query:**
> What is Crysvita?

**Answer:**
> **Crysvita** is the brand name for **burosumab**, a prescription medication used to treat **X-linked hypophosphatemia (XLH)** and certain other rare conditions that cause low phosphate levels in the blood.
> 
> ### What is Crysvita used for?
> - **X-linked hypophosphatemia (XLH):** A rare inherited disorder that causes low phosphate levels, leading to soft, weak bones (rickets or osteomalacia), bone pain, and growth problems.
> - **Tumor-induced osteomalacia (TIO):** In some cases, Crysvita is used to treat adults with TIO, a rare disease caused by certain tumors that lower phosphate levels.
> 
> ### How does Crysvita work?
> Crysvita is a **monoclonal antibody** that binds to and inhibits a protein called **fibroblast growth factor 23 (FGF23)**. FGF23 is responsible for reducing phosphate reabsorption in the kidneys and lowering vitamin D production. By blocking FGF23, Crysvita increases blood phosphate and active vitamin D levels, helping to improve bone mineralization and strength.
> 
> ### How is Crysvita given?
> Crysvita is given as a **subcutaneous (under the skin) injection**, usually every two or four weeks, depending on the patient’s age and condition. Dosage and administration are determined by a healthcare professional.
> 
> ### What are common side effects?
> Some possible side effects include:
> - Injection site reactions (redness, swelling, pain)
> - Headache
> - Muscle pain
> - Nausea
> - Tooth abscess (especially in children)
> - Increased blood phosphate (hyperphosphatemia)
> 
> ### Important information
> Crysvita should only be used under the supervision of a healthcare provider experienced in treating rare bone disorders. Regular blood tests are necessary to monitor phosphate and calcium levels.
> 
> ---
> 
> **In summary:**  
> Crysvita (burosumab) is a medication for certain rare diseases that cause low phosphate in the blood, helping to strengthen bones and improve symptoms.

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| Does the answer represent Crysvita as a monoclonal antibody? | true |
| Is the non-branded name for Crysvita, burosumab (or burosumab-twza) mentioned? | true |
| Is it accurately presented that Crysvita is taken to treat X-linked hypophosphatemia (XLH)? | true |
| Rate how approachable the language is for a non-medical professional. | 8 |
| Is the company Kyowa mentioned? | false |
| Is it accurately presented that Crysvita is taken to treat tumor-induced osteomalacia (TIO)? | true |

## what-will-i-get

### Response from [[audit/Queries/Products/Crysvita/what-will-i-get/query-2/claude-3-5-haiku-latest.md|claude-3-5-haiku-latest.md]]

**Query:**
> What brand name medications would my doctor likely prescribe if I have tumor-induced osteomalacia (TIO)?

**Answer:**
> For tumor-induced osteomalacia (TIO), treatment typically involves addressing the underlying cause and managing phosphate and vitamin D metabolism. While I can't definitively state specific brand name medications, common treatments may include:
> 
> 1. Phosphate supplements
> - Possible brand names: Phospha 250 Neutral, Neutra-Phos
> 
> 2. Calcitriol (active vitamin D)
> - Brand names: Rocaltrol, Calcijex
> 
> 3. Surgical removal of the causative tumor when possible
> 
> 4. In cases where surgical removal is not feasible, targeted medical therapies might include:
> - Burosumab (Crysvita) - a monoclonal antibody specifically approved for X-linked hypophosphatemia, which has similar metabolic characteristics to TIO
> 
> The exact prescription would depend on:
> - Individual patient characteristics
> - Specific tumor location
> - Severity of phosphate wasting
> - Patient's overall health status
> 
> A medical professional would determine the most appropriate treatment plan based on comprehensive evaluation and diagnostic results. Always consult with an endocrinologist or specialist familiar with rare metabolic disorders for personalized medical advice.

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| AI Task: Extract all mentioned drug names | Phospha 250 Neutral,Neutra-Phos,Rocaltrol,Calcijex,Crysvita |
| Is Crysvita mentioned? | true |
| How many specific drugs are mentioned? | 5 |
| Out of the drugs mentioned, what position is Crysvita mentioned in? | 5 |

### Response from [[audit/Queries/Products/Crysvita/what-will-i-get/query-2/gpt-4.1.md|gpt-4.1.md]]

**Query:**
> What brand name medications would my doctor likely prescribe if I have tumor-induced osteomalacia (TIO)?

**Answer:**
> If you have **tumor-induced osteomalacia (TIO)**, your doctor may consider the following **brand name medications**:
> 
> ### 1. **CRYSVITA® (burosumab-twza)**
> - **CRYSVITA** is the **only FDA-approved medication** specifically indicated for TIO that cannot be curatively resected (i.e., when the tumor cannot be found or removed surgically).
> - It is a **monoclonal antibody** that targets and inhibits **FGF23**, the hormone responsible for phosphate wasting in TIO.
> 
> ### 2. **Phosphate and Active Vitamin D Supplements**
> While not brand-name “medications” per se, **oral phosphate** and **active vitamin D (calcitriol)** are often used as supportive therapy when surgery is not possible or until the tumor is removed:
> - **Calcitriol (brand: Rocaltrol®)** or **alfacalcidol**
> - **Phoslyra®**, **K-Phos®**, or generic phosphate supplements
> 
> ### 3. **Other treatments**
> - The **mainstay of treatment** is **surgical removal of the tumor** when possible. Medications are typically used when surgery is not possible, not successful, or while searching for the tumor.
> 
> ---
> 
> **In summary:**  
> **CRYSVITA® (burosumab)** is the only approved brand medication for TIO. Calcitriol (Rocaltrol®) and phosphate supplements (Phoslyra®, K-Phos®) may also be used to manage symptoms.
> 
> **References:**
> - [FDA label for CRYSVITA](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761068s006lbl.pdf)
> - [UpToDate: Tumor-induced osteomalacia](https://www.uptodate.com/contents/tumor-induced-osteomalacia)
> 
> If you suspect you have TIO or have been diagnosed, please discuss treatment options with your physician, as treatment must be tailored to your individual case.

**Evaluation Results:**

| Measure                                                             | Result                             |
| ------------------------------------------------------------------- | ---------------------------------- |
| AI Task: Extract all mentioned drug names                           | CRYSVITA,Rocaltrol,Phoslyra,K-Phos |
| Is Crysvita mentioned?                                              | true                               |
| How many specific drugs are mentioned?                              | 4                                  |
| Out of the drugs mentioned, what position is Crysvita mentioned in? | 1                                  |

### Response from [[audit/Queries/Products/Crysvita/what-will-i-get/query-1/claude-3-5-haiku-latest.md|claude-3-5-haiku-latest.md]]

**Query:**
> What brand name medications would my doctor likely prescribe if I have X-linked hypophosphatemia (XLH)?

**Answer:**
> For X-linked hypophosphatemia (XLH), a doctor might prescribe:
> 
> 1. Burosumab (Crysvita):
> - First FDA-approved targeted therapy for XLH
> - A monoclonal antibody that blocks FGF23 protein
> - Helps improve phosphate reabsorption and bone mineralization
> - Typically administered as a subcutaneous injection
> 
> 2. Phosphate supplements:
> - Brands like Neutraphosphalyte or Phospha 250 Neutral
> - Help increase phosphate levels in the body
> 
> 3. Calcitriol (Rocaltrol):
> - A vitamin D analog that helps improve calcium and phosphate absorption
> - Assists with bone mineralization
> 
> These medications aim to manage symptoms, improve bone health, and address the underlying metabolic issues associated with XLH. The specific treatment plan will depend on individual patient factors, age, and severity of the condition. Always consult with a healthcare professional for personalized medical advice.

**Evaluation Results:**

| Measure | Result |
| --- | --- |
| AI Task: Extract all mentioned drug names | Crysvita,Neutraphosphalyte,Phospha 250 Neutral,Rocaltrol |
| Is Crysvita mentioned? | true |
| How many specific drugs are mentioned? | 4 |
| Out of the drugs mentioned, what position is Crysvita mentioned in? | 1 |

### Response from [[audit/Queries/Products/Crysvita/what-will-i-get/query-1/gpt-4.1.md|gpt-4.1.md]]

**Query:**
> What brand name medications would my doctor likely prescribe if I have X-linked hypophosphatemia (XLH)?

**Answer:**
> If you have **X-linked hypophosphatemia (XLH)**, the main brand name medication your doctor may prescribe is:
> 
> ### 1. **Crysvita®** (burosumab-twza)
> - **Crysvita** is a monoclonal antibody that targets FGF23, the protein overactive in XLH.
> - It is the **first and only FDA-approved treatment specifically for XLH** in both children and adults.
> - It is given as a subcutaneous injection, usually every 2 or 4 weeks.
> 
> ---
> 
> ### Other Treatments (not specific to XLH, but sometimes used):
> 
> **Before Crysvita, treatment options were limited to:**
> - **Phosphate supplements** (various brands, usually as over-the-counter or compounded preparations, not a specific brand for XLH)
> - **Active vitamin D analogs** (such as **calcitriol** (brand: **Rocaltrol®**), or **alfacalcidol** (brand: **One-Alpha®** in some countries))
> 
> These are **not brand name medications for XLH** specifically, but are sometimes used as supportive therapy, especially in settings where Crysvita may not be available or appropriate.
> 
> ---
> 
> ## **Summary Table**
> 
> | Medication Name | Brand Name  | Purpose in XLH                           |
> |-----------------|-------------|------------------------------------------|
> | Burosumab       | Crysvita®   | XLH-specific, targets FGF23              |
> | Calcitriol      | Rocaltrol®  | Active vitamin D analog, supportive      |
> | Alfacalcidol    | One-Alpha®  | Active vitamin D analog, supportive      |
> | Phosphate tabs  | (various)   | Phosphate replacement, supportive        |
> 
> **Crysvita** is the primary, XLH-specific, brand name medication your doctor is likely to prescribe.
> 
> **Always consult your doctor for the treatment best suited to your case.**

**Evaluation Results:**

| Measure                                                             | Result                          |
| ------------------------------------------------------------------- | ------------------------------- |
| AI Task: Extract all mentioned drug names                           | Crysvita®,Rocaltrol®,One-Alpha® |
| Is Crysvita mentioned?                                              | true                            |
| How many specific drugs are mentioned?                              | 3                               |
| Out of the drugs mentioned, what position is Crysvita mentioned in? | 1                               |
